HomeAI · summaries
Storia in 2 fonti
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study - ProMI
ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Preliminary trial results suggest a path to a safer Alzheimer's treatment
ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
- ·
benzinga.com
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study - ProMI
ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.